Samit Hirawat, Bristol Myers CMO

FDA OKs Bris­tol My­ers Squibb’s LAG-3 drug, ap­prov­ing first new class of check­point in­hibitor in 8 years

For the first time in near­ly a decade, the FDA has ap­proved a new type of check­point in­hibitor to treat cer­tain pa­tients with can­cer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.